Nirmish Singla is an Oncologist in Lutherville, Maryland. Dr. Singla is rated as an Elite provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Upper Tract Urothelial Carcinoma (UTUC), Renal Cell Carcinoma (RCC), Urothelial Cancer, Nephrectomy, and Orchiectomy.

Dr. Jean Hoffman-Censits is a genitourinary cancer specialist in Baltimore, caring for patients with urothelial cancers of the bladder and upper tract. She serves as co-leader of the Women’s Bladder Cancer Program in the Greenberg Bladder Cancer Institute at the Johns Hopkins University School of Medicine. Dr. Hoffman-Censits received her undergraduate degree in neuroscience from Trinity College. She earned her M.D. degree from the Sidney Kimmel Medical College of Thomas Jefferson University. She completed her residency at Thomas Jefferson University Hospital and performed a fellowship in hematology and oncology at Temple University Medical Center. She joined the Johns Hopkins faculty in 2018. Dr. Hoffman-Censits's research interests focus on urothelial cancers. Her clinical research has helped identify urothelial cancer sub-types and establish new treatments for bladder and upper tract urothelial cancers. She is a member of the American Medical Association, the American Society of Clinical Oncology, the American Urological Association and the Society for Immunotherapy of Cancer. Dr. Hoffman is rated as an Elite provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). Her top areas of expertise are Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Nephrectomy, and Bladder Reconstruction.

Dr. Noah Hahn is a medical oncologist in the Baltimore area, caring for patients with bladder cancer. He serves as the deputy director of the Greenberg Bladder Cancer Institute at the Johns Hopkins School of Medicine. Dr. Hahn earned his M.D. from Indiana University School of Medicine. He completed his residency in internal medicine at Duke University School of Medicine and performed a fellowship in medical oncology at Indiana University School of Medicine. Dr. Hahn joined the Johns Hopkins faculty in 2014. Prior to joining Johns Hopkins, Dr. Hahn was the director of the Genitourinary Medical Oncology Program at Indiana University and chief scientific officer for the Hoosier Oncology Group, a cancer research organization that evaluates innovative and promising approaches to cancer treatment. He is currently conducting clinical trials to test new therapies for bladder cancer, including those for early stage bladder cancer. Dr. Hahn is a member of the Bladder Cancer Task Force for the National Cancer Institute’s Genitourinary Cancer Steering Committee and is chair of the Bladder Cancer Subcommittee of the Eastern Cooperative Oncology Group. Dr. Hahn is rated as an Elite provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Upper Tract Urothelial Carcinoma (UTUC), and Nephrectomy.

Dr. Max Kates is the R. Christian B. Evensen Professor and an associate professor of urology and oncology at the Brady Urological Institute at Johns Hopkins. He also directs the Division of Urologic Oncology for the Brady Urological Institute. Dr. Kates completed his undergraduate degree at Wesleyan University in Connecticut before pursuing his medical degree at Mount Sinai School of Medicine in New York. He then went on to train at Johns Hopkins for his urologic residency and Society of Urologic Oncology (SUO) fellowship. Dr. Kates has expertise in all areas of urologic oncology, with a particular emphasis on bladder and prostate cancer. With training in open, endoscopic, and robotic surgical approaches, Dr. Kates’ surgical philosophy is to assess the unique needs of each patient, and develop the right treatment plan for their malignancy. He is very hands on in his approach in the clinic and the operating room, and believes open communication with the patient, the patient’s family, and referring providers is key to ensuring a speedy recovery. As the clinical director of the bladder cancer multidisciplinary clinic, Dr. Kates works with the team at the Johns Hopkins Greenberg Bladder Cancer Institute to deliver a personalized approach to bladder cancer utilizing cutting edge precision medicine approaches. Dr. Kates’ research interests involve novel treatments for cancers of the urinary tract. Dr. Kates has authored more than 135 journal articles in the fields of bladder, prostate, and kidney cancer. He currently has a provisional patent for a novel intravesical chemotherapy developed with nano-engineer collaborators. Additionally, Dr. Kates has made important discoveries into the mechanism of action of intravesical BCG, the most common treatment for bladder cancer. He is the principal investigator on multiple trials, and is currently leading EA8212 BRIDGE, which is a randomized trial open in over 150 centers in the United States comparing BCG to GemDoce chemotherapy for early stage bladder cancer. To inquire about an appointment or make a referral, Dr. Kates can be contacted by phone (410) 614-0009. Dr. Kates is rated as an Advanced provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Nephrectomy.

Dr. John Migaly is a distinguished colorectal surgeon and Chief of the Division of Colorectal Surgery/Ravitch Division at Johns Hopkins Medicine. He specializes in the treatment of colorectal cancer, inflammatory bowel disease, and other benign and complex colorectal conditions. Dr. Migaly is committed to providing advanced, patient-centered care, often using minimally invasive techniques including laparoscopic and robotic surgery, to help reduce recovery time and improve outcomes. Dr. Migaly comes to Johns Hopkins Medicine from the Duke University School of Medicine, serving from 2008-2024 on the surgery faculty treating patients primarily through the Duke Cancer Institute. He was elevated to Program Director of the General Surgery Residency in 2012, and subsequently served as Vice Chair of Education until 2024. His work was critical to the success of the undergraduate, graduate, and continuing medical education missions at Duke Surgery. Dr. Migaly earned his B.A. in Biochemistry from New York University and his medical degree from the New York University School of Medicine. He completed surgical residency and a research fellowship at Temple University Health Sciences Center, and colorectal surgery fellowship at Cleveland Clinic Florida. Dr. Migaly’s career has been marked not only by a complex and high-volume clinical colon and rectal surgery practice, but also a commitment to research and education, supported by greater than 200 publications, book chapters, and presentations. His research is centered around improving practice patterns and outcomes in colorectal cancer care and recovery. His leadership and dedication to advancing the field of colorectal surgery is evident through his service on committees that shape how colorectal care is delivered nationally, via his past and present service on the Program Committee, the Clinical Practice Guidelines Committee and the Diversity and Inclusion Committee of the American Society of Colon and Rectal Surgeons. Videos John Migaly, M.D.Chief of Colorectal Surgery"". Dr. Migaly is rated as an Advanced provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Familial Colorectal Cancer, Gastroesophageal Junction Cancer, Anal Cancer, Colostomy, and Ileostomy.

Kasey Morrison is an Urologist in Silver Spring, Maryland. Dr. Morrison has been practicing medicine for over 17 years and is rated as an Experienced provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Neurogenic Bladder, Bilateral Hydronephrosis, Hydronephrosis, Ureteroscopy, and Prostatectomy. Dr. Morrison is currently accepting new patients.

Md Siddiqui is a Hematologist Oncology specialist and a Hematologist in Salisbury, Maryland. Dr. Siddiqui is rated as an Experienced provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Pulmonary Embolism, Inflammatory Breast Cancer, Angiosarcoma, and Childhood Iron Deficiency Anemia. Dr. Siddiqui is currently accepting new patients.

Jonathan Rhee is an Urologist in Silver Spring, Maryland. Dr. Rhee is rated as an Experienced provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are UPJ Obstruction, Bilateral Hydronephrosis, Hydronephrosis, Ureteroscopy, and Prostatectomy. Dr. Rhee is currently accepting new patients.

Rian Dickstein is an Urologist in Baltimore, Maryland. Dr. Dickstein is rated as a Distinguished provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Hydronephrosis, Ureteroscopy, and Nephrectomy. Dr. Dickstein is currently accepting new patients.

David Smith is a Hematologist and an Oncologist in Easton, Maryland. Dr. Smith is rated as a Distinguished provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Thrombocytopenia, Hemangioma Thrombocytopenia Syndrome, Adult Immune Thrombocytopenia, and Myelodysplastic Syndrome (MDS).

Richard Cespedes is an Urologist in Easton, Maryland. Dr. Cespedes is rated as a Distinguished provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Urinary Incontinence, Stress Urinary Incontinence, Urinary Tract Infection in Children, Upper Tract Urothelial Carcinoma (UTUC), and Ureteroscopy. Dr. Cespedes is currently accepting new patients.

Gary Kazlow is a Pulmonary Medicine provider in Elkridge, Maryland. Dr. Kazlow is rated as an Experienced provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Empyema, Bronchitis, Upper Tract Urothelial Carcinoma (UTUC), and Lung Metastases.

Arun Rai, M.D., M.B.A., M.S., is a urologist who specializes in minimally invasive surgery and endourology and has extensive training to treat patients with adrenal cancer, kidney cancer, ureteral cancer and prostate cancer. In addition, he also specializes in treating patients with BPH, kidney stones and bladder stones. Dr. Rai earned both his undergraduate and medical degrees through the highly selective seven-year accelerated medical education program at Boston University School of Medicine. Dr. Rai went on to complete a general surgery internship at Baylor College of Medicine, where he then also completed his urology residency. Dr. Rai continued his training at the Northwell Health’s Smith Institute for Urology by completing a fellowship in Endourology and Minimally Invasive Surgery. During this time, he also received a dual MBA/MS in Healthcare Leadership Weill Cornell Graduate School of Medical Sciences and Cornell University. In addition to caring for patients, Dr. Rai serves as Clinical Director for the Brady Urological Institute's Quantitative Data Sciences division. His research focuses on developing the next generation of surgical technology, focusing on artificial intelligence and machine learning for optimizing clinical care. He strongly believes that surgeons should have an active role in the development of the next generation of tools for the optimal treatment of patients. He has authored several publications, with topics including patient safety in the operating room, long-term outcomes of subcapsular renal hematoma, pelvi-ureteric junction obstruction and featured in journals such as Urology and the Journal of Endourology. Dr. Rai is rated as an Experienced provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Kidney Stones, Horseshoe Kidney, Boils, Ureteroscopy, and Lithotripsy.

Sunil H. Patel, M.D., M.A., is an Assistant Professor of Urology and Oncology at the School of Medicine at Johns Hopkins. He serves as and the Director of the Urologic Oncology Fellowship. He also serves as Director of the Testicular Cancer program. He treats all urologic malignancies, including adrenal cancer, kidney cancer, urothelial cancer, bladder cancer, prostate cancer, testes cancer, and penile cancers. Additionally, he has advanced training in complex robotic and open surgical cases. His clinical and research focus is in Urologic Oncology, with areas of focus in bladder cancer, testes cancer, and kidney cancer. Dr. Patel completed his undergraduate studies at California Polytechnic State University, San Luis Obispo where he studied Biological Sciences. He completed his Masters at Boston University, completing his thesis on microfluidics, afterwards completing his medical degree at Boston University. He completed his general surgery internship and urology residency at University of California, San Diego. He continued his training through a Society of Urologic Oncology Fellowship in urologic oncology at the Johns Hopkins Hospital. He joined Johns Hopkins in June 2020 with interests in environmental factors contributing to oncogenesis in urological cancers, especially bladder cancer. He is dedicated to international health and works closely with international volunteers in urology and has done several mission trips and guest lectures. Dr. Patel is rated as an Experienced provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Bladder Cancer, Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Nephrectomy, and Reconstructive Urology Surgery.

Naren Nimmagadda, M.D., is an assistant professor of urology at the Johns Hopkins University School of Medicine. He treats a wide range of benign and malignant urological conditions. As a fellowship trained urologist in endourologic and laparoscopic surgery, his practice focuses on treated voiding issues related to BPH through Holmium Laser Enucleation of the Prostate (HoLEP), an alternative to transurethral resection of the prostate (TURP). Dr. Nimmagadda also specializes in treating kidney, ureteral and bladder stones via shockwave lithotripsy, endoscopic and percutaneous techniques. Dr. Nimmagadda is the Endourology, Minimally Invasive Urology Fellowship Program Director. Dr. Nimmagadda attended medical school at the University of Maryland School of Medicine. Following medical school, Dr. Nimmagadda completed a general surgery internship and residency in urology at Massachusetts General Hospital. He then completed a fellowship in endourology and laparoscopic surgery at Vanderbilt University Medical Center. Following graduation, Dr. Nimmagadda served on the Vanderbilt University Medical Center’s Department of Urology faculty as an instructor. Dr. Nimmagadda has research interest in the intersection of urology and technological innovation. Dr. Nimmagadda is rated as an Experienced provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Kidney Stones, Enlarged Prostate (BPH), UPJ Obstruction, Ureteroscopy, and Lithotripsy.

As an active participant in the medical community, Mohit Narang, M.D. has served as a primary investigator and research assistant on many trials. During Dr. Narang’s fellowship, he was honored with the invitation to attend the Masterclass in Clinical Oncology at Montecatini, Italy by the European School of Oncology. He holds professional memberships with the American Society of Clinical Oncology, American Society of Hematology, as well as the European Society of Medical Oncology. Learn more at marylandoncology.com. Dr. Narang is rated as an Experienced provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Multiple Myeloma, Agranulocytosis, Paget Disease of the Breast, Thrombocytopenia, and Bone Marrow Transplant.

Dr. Christian Pavlovich is Bernard L. Schwartz Distinguished Professor in Urologic Oncology at the Johns Hopkins University School of Medicine and Director of the Prostate Cancer Active Surveillance Program at the Brady Urological Institute. Dr. Pavlovich treats cancer with an emphasis on minimizing morbidity and maximizing quality of life while offering patients the latest treatment options and techniques. His clinical focus is on prostate and kidney cancer, and on clinical trials regarding detection, surveillance, and immunotherapy. With more than 20 years of experience with minimally-invasive surgery for the treatment of urologic cancers, he is expert in robotic surgery and was named one of the top prostate cancer surgeons in the United States by Newsweek in 2024. In addition, he offers patients modern diagnostic biopsy techniques, and for prostate cancer patients active surveillance and ablative options including cryotherapy and TULSA. Dr. Pavlovich grew up in Washington DC, went to Harvard University, and then earned his medical degree at the University of California, San Francisco (UCSF) School of Medicine. He then completed a urology residency at New York Hospital-Cornell Medical Center and a National Cancer Institute SUO fellowship in urologic oncology before joining the Hopkins faculty in 2001. Dr. Pavlovich has published over 150 peer-reviewed articles, is Associate Editor of The Prostate and is on the Editorial Board of the British Journal of Urology International. He was the inaugural Director of the Brady Urological Institute’s SUO Urologic Oncology Fellowship (2014 -2024) and is the recipient of three “best teaching/research mentor” awards from the Urology residents at Johns Hopkins. Dr. Pavlovich speaks English, French, Spanish, German, and Serbo-Croatian. He enjoys spending time with his wife and children, following their pursuits, and skiing, diving, running, wildlife, and the great outdoors. Dr. Pavlovich is rated as an Experienced provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Prostatectomy, and Nephrectomy.

William Houck is an Oncologist in Baltimore, Maryland. Dr. Houck is rated as an Experienced provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Paget Disease of the Breast, Lung Cancer, Chronic B-Cell Leukemia (CBCL), and Chronic Lymphocytic Leukemia (CLL).

Arvin K. George, MD, is a urologic surgeon specializing in the diagnosis and management of genitourinary cancers, with particular sub-specialization in kidney and prostate cancers. His clinical interests and expertise are in image-guided therapeutics, and minimally-invasive ablative/surgical techniques for prostate and kidney cancer. These include laparoscopic and robotic surgery, in addition to cryoablation, high-intensity focused ultrasound ablation, nanoparticle directed laser ablation, laser interstitial thermal therapy, and bipolar radiofrequency ablation. Dr. George obtained his medical degree from the Royal College of Surgeons in Ireland, followed by a urology residency at the Smith Institute for Urology, Hofstra North Shore-LIJ School of Medicine. He remained to complete his endourology/minimally-invasive and robotic surgery fellowship in New York gaining additional subspecialty expertise in robotic, laparoscopic, and percutaneous surgery. Subsequently, he completed a urologic oncology fellowship at the National Cancer Institute, National Institutes of Health. He then joined the clinical facility at the University of Michigan, Ann Arbor, where he directed the Prostate Cancer Programs from 2019 through 2023. Dr. George participates extensively in the discovery of urologic science and evaluation of urologic care and has co-authored over 80 peer reviewed publications. Additionally, he has authored 11 chapters in medical education books. Dr. George sees patients in clinic throughout the Baltimore region and also is available for virtual appointments for patients in Maryland, Washington D.C., New York and Michigan. Dr. George is rated as an Experienced provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Prostatectomy, and Nephrectomy.

Dung Le, M.D. is a professor of oncology at the Johns Hopkins University School of Medicine and member of the Johns Hopkins Kimmel Cancer Center. Her research interests include novel approaches to patients with gastrointestinal malignancies. She has served as the principal investigator (PI) on many clinical trials focused on testing immunotherapy in patients with gastrointestinal malignancies and she has also served as the national PI on several studies including: anti-programmed death-1 (PD-1) in tumors with mismatch repair deficiency; a clinical trial in advanced pancreatic cancer patients evaluating the safety, tolerability and immune response to CRS-207, a listeria vaccine platform which has been modified to express the tumor antigen mesothelin; a multi-center, phase 2 study testing CRS-207 as a boost to allogenic pancreatic tumor cells transfected with GM-CSF gene (GVAX) for treatment of advanced pancreatic adenocarcinoma (PDA); a trial testing GVAX/ipilimumab in the maintenance setting for metastatic pancreatic cancer; and GVAX/CRS-207 +/- nivolumab in metastatic pancreatic cancer. These studies incorporate extensive laboratory correlates and have involved collaborations with clinicians and bench scientists with expertise in the fields of immunotherapy and cancer genomics. Dr. Le is rated as an Experienced provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). Her top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Gastroesophageal Junction Cancer, and Familial Pancreatic Cancer.